Research + insights

Explore the following resources on medication-assisted treatment, including original research that Ophelia has published in leading scientific journals. We're always looking for better ways to care for patients, and we're committed to sharing this knowledge with the world.

Featured

Peer Reviewed Journal

Use of in-network insurance benefits is critical for improving retention in telehealth-based buprenorphine treatment

Arthur Robin Williams, MD
Christopher Rowe, PhD
Lexie-Minarik
Zack Gray
Sean M. Murphy

We conducted a study and found that almost 3/4 of Ophelia patients who had in-network insurance stayed in treatment for more than six months. Read article here.

Peer Reviewed Journal

Urine Drug Screening in a Telehealth Setting for the Treatment of Opioid Use Disorder

Arthur Robin Williams, MD
Christopher Rowe, PhD
Shoshana V. Aronowitz, PhD
Jon Diamond-Reivich
Adam Bisaga, MD

Remote urine drug testing can be successfully adapted to exclusively virtual telehealth settings. Ophelia provides real-time, face-to-face high-quality care adherent to in-person best practices. Read more.

Peer Reviewed Journal

A virtual-first telehealth treatment model for opioid use disorder

Arthur Robin Williams, MD
Adam Bisaga, MD
Zack Gray
Ryan Gallagher, MD
Shoshana V. Aronowitz, PhD

Telehealth for OUD holds promise to rapidly scale high quality accessible care for individuals affected by the opioid crisis. Read more.

Peer Reviewed Journal

Implementation and evaluation of a telehealth opioid use disorder clinical placement for nurse practitioner students.

Data Brief

Characteristics, care measures, and clinical outcomes of insured Ophelia patients.

Peer Reviewed Journal

Telehealth for opioid use disorder: retention as a function of demographics and rurality.

White paper

Virtual care for opioid use disorder: An evidence- and value-based approach.

Peer Reviewed Journal

Developing an opioid use disorder treatment cascade: A review of quality measures.

Peer Reviewed Journal

Acute care, prescription opioid use, and overdose following discontinuation of long-term buprenorphine treatment for opioid use disorder.

Peer Reviewed Journal

Impact of long-term buprenorphine treatment on adverse health care outcomes in Medicaid.

Peer Reviewed Journal

Risk factors for discontinuation of buprenorphine treatment for opioid use disorders in a multi-state sample of Medicaid enrollees.

Peer Reviewed Journal

Non-prescribed buprenorphine preceding treatment intake and clinical outcomes for opioid use disorder.

Peer Reviewed Journal

Psychosocial and behavioral therapy in conjunction with medication for opioid use disorder: Patterns predictors and association with buprenorphine treatment outcomes.

Ophelia's patient outcomes

85% of Ophelia patients attend follow-up visits in the early weeks of treatment, more than 5x the national average (HEDIS: Engagement of AOD Treatment).

79% of Ophelia patients are retained in treatment at 180 days, more than 2x the national average(HEDIS: Pharmacotherapy for Opioid Use Disorder).

Ophelia earns a Net Promoter Score (NPS) of 97 among patients, 3x the industry average.